NanoBio Closes Series B Round
NanoBio Corp., an Ann Arbor, Mich.-based developer of anti-infective products and mucosal vaccines, has raised $10 million in additional Series B funding, closing out the round at $22 million. Venture Investors were joined by return backer Perseus LLC. The company has now raised $52 million in total VC funding, plus nearly $40 million in grant funding.
8 July 2009•2 mins read
